BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score.
Mark D ZarellaRebecca C HeintzelmanNikolay K PopnikolovFernando U GarciaPublished in: BMC clinical pathology (2018)
Our results demonstrate an improvement in concordance between immunohistochemistry-based and gene expression-based methods to predict breast cancer recurrence risk following two simple modifications to the conventional scoring model.